CAMBRIDGE, Mass. & CHARLOTTE, N.C.--(BUSINESS WIRE)--Despite advances in treatment and clear guidelines, many patients with diabetes are failing to achieve target glucose levels both in the inpatient and outpatient setting. One of the main challenges posing a barrier is clinical inertia preventing the initiation and intensification of insulin therapy. Insulin therapy has been proven to significantly reduce hemoglobin A1c levels in individuals with diabetes and better manage hyperglycemia, yet countless studies show that insulin initiation and intensification is frequently and inappropriately delayed.
Monarch and Voluntis, who formed a business relationship last year, are partnering to offer a complimentary webinar, “How Technology Can Support Adoption of Best Practices for Inpatient and Outpatient Insulin Management.” The webinar will discuss the current challenges in initiating and managing insulin therapy, review the recommended practices in both the inpatient and outpatient setting, and discuss how technology can be used and implemented to benefit both patients and providers.
You may register for the webinar here.
Tuesday, June 25, 2019 at 12:00 pm EST
Amy Butts PA-C, MPAS, CDE, BC-ADM, Endocrine Physician Assistant, Wheeling Hospital
Mark Vanderwel, MD, Medical Director of the Pediatric Endocrinology Division, Atrium Health
- Discuss the difficulties that providers and patients have with managing insulin dosing
- Review the 2019 ADA Standards of Medical Care in Diabetes for insulin management
- Provide examples of how technology can support inpatient and outpatient insulin titration
- Describe strategies to integrate technology into your environment
Following the live webinar, a recording will be available to download on monarchmedtech.com within 24 hours of the live event.
About Monarch Medical Technologies
Monarch Medical Technologies is the leading provider of electronic systems for inpatient glycemic management. Monarch’s EndoTool® Glucose Management System offers personalized dosing recommendations for intravenous and subcutaneous insulin therapy. As a Class II FDA-cleared, patented software suite, EndoTool has been chosen by more than 300 hospitals to provide unsurpassed patient-specific glycemic control across a broad population of patients, and ultimately deliver better, safer care. For more information, please visit monarchmedtech.com.
Voluntis creates digital therapeutics that empower people suffering from
chronic conditions to self- manage their treatment every day, thus
improving real-world outcomes. Combining mobile and web apps, Voluntis’
solutions deliver personalized recommendations to the patient and the
care team so that they can, for example, adjust treatment dosage, manage
side effects or monitor symptoms. These real- time recommendations are
based on digitized clinical algorithms. Leveraging its Theraxium
technology platform, Voluntis has designed and operates multiple digital
therapeutics, especially in diabetes and oncology. Voluntis has
long-standing partnerships with leading life science companies such as
Abbvie, AstraZeneca, Roche, Sanofi and Onduo. Based out of Boston and
Paris, France, Voluntis is a founding member of the Digital Therapeutics
Alliance. For further information: http://www.voluntis.com.
Voluntis is traded on the Euronext Paris – Compartment C market
Ticker: VTX – ISIN: FR0004183960
Diabeo® is a registered trademark of Sanofi. Insulia® is a registered trademark of Voluntis.
For further information: http://www.voluntis.com